WO2001022791A3 - Controlled release compositions comprising nimesulide - Google Patents

Controlled release compositions comprising nimesulide Download PDF

Info

Publication number
WO2001022791A3
WO2001022791A3 PCT/IN2000/000094 IN0000094W WO0122791A3 WO 2001022791 A3 WO2001022791 A3 WO 2001022791A3 IN 0000094 W IN0000094 W IN 0000094W WO 0122791 A3 WO0122791 A3 WO 0122791A3
Authority
WO
WIPO (PCT)
Prior art keywords
nimesulide
controlled release
release compositions
dosage form
oral dosage
Prior art date
Application number
PCT/IN2000/000094
Other languages
French (fr)
Other versions
WO2001022791A2 (en
WO2001022791A8 (en
Inventor
Amarjit Singh
Rajesh Jain
Original Assignee
Panacea Biotec Ltd
Amarjit Singh
Rajesh Jain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU28799/01A priority Critical patent/AU774099B2/en
Priority to HU0204451A priority patent/HUP0204451A3/en
Application filed by Panacea Biotec Ltd, Amarjit Singh, Rajesh Jain filed Critical Panacea Biotec Ltd
Priority to NZ518052A priority patent/NZ518052A/en
Priority to AT00992052T priority patent/ATE450865T1/en
Priority to UA2002032356A priority patent/UA80667C2/en
Priority to EP00992052A priority patent/EP1218889B1/en
Priority to PL358369A priority patent/PL203507B1/en
Priority to JP2001526021A priority patent/JP4359412B2/en
Priority to IL14886400A priority patent/IL148864A0/en
Priority to CA002385890A priority patent/CA2385890C/en
Priority to MXPA02003321A priority patent/MXPA02003321A/en
Priority to DE60043447T priority patent/DE60043447D1/en
Priority to BR0014383-9A priority patent/BR0014383A/en
Priority to DK00992052.1T priority patent/DK1218889T3/en
Publication of WO2001022791A2 publication Critical patent/WO2001022791A2/en
Publication of WO2001022791A3 publication Critical patent/WO2001022791A3/en
Priority to IL148864A priority patent/IL148864A/en
Priority to NO20021540A priority patent/NO20021540L/en
Priority to BG106605A priority patent/BG66093B1/en
Publication of WO2001022791A8 publication Critical patent/WO2001022791A8/en
Priority to US11/545,718 priority patent/US20070128276A1/en
Priority to US11/978,162 priority patent/US20080160082A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891Coated capsules; Multilayered drug free capsule shells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/2853Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A Controlled release pharmaceutical composition of Nimesulide comprising Nimesulide, as an active drug, one or more sustaining materials and pharmaceutical excipients formulated into a controlled release once-a-day oral dosage form.
PCT/IN2000/000094 1999-09-28 2000-09-27 Controlled release compositions comprising nimesulide WO2001022791A2 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
IL14886400A IL148864A0 (en) 1999-09-28 2000-09-27 Pharmaceutical compositions containing nimesulide
CA002385890A CA2385890C (en) 1999-09-28 2000-09-27 Controlled release compositions comprising nimesulide
NZ518052A NZ518052A (en) 1999-09-28 2000-09-27 Controlled release compositions comprising nimesulide (4-nitro-2-phenoxymethanesulfonanilide) for a once-a-day oral dosage to treat diseases such as arthritis
AT00992052T ATE450865T1 (en) 1999-09-28 2000-09-27 CONTROLLED RELEASE COMPOSITIONS CONTAINING NIMESULIDE
UA2002032356A UA80667C2 (en) 1999-09-28 2000-09-27 Controlled release composition comprising nimesulide and process for the preparation thereof
EP00992052A EP1218889B1 (en) 1999-09-28 2000-09-27 Controlled release compositions comprising nimesulide
PL358369A PL203507B1 (en) 1999-09-28 2000-09-27 Controlled release pharmaceutical composition containing nimesulide and a method of its preparation
JP2001526021A JP4359412B2 (en) 1999-09-28 2000-09-27 Controlled release composition comprising nimesulide
DE60043447T DE60043447D1 (en) 1999-09-28 2000-09-27 COMPOSITIONS WITH CONTROLLED RELEASE CONTAINING NIMESULID
AU28799/01A AU774099B2 (en) 1999-09-28 2000-09-27 Controlled release compositions comprising nimesulide
MXPA02003321A MXPA02003321A (en) 1999-09-28 2000-09-27 Controlled release compositions comprising nimesulide.
HU0204451A HUP0204451A3 (en) 1999-09-28 2000-09-27 Controlled release compositions comprising nimesulide
BR0014383-9A BR0014383A (en) 1999-09-28 2000-09-27 Controlled release compositions comprising nimesulide
DK00992052.1T DK1218889T3 (en) 1999-09-28 2000-09-27 Controlled release compositions comprising nimesulide
IL148864A IL148864A (en) 1999-09-28 2002-03-25 Pharmaceutical compositions containing nimesulide
NO20021540A NO20021540L (en) 1999-09-28 2002-03-27 Controlled release compositions comprising nimesulfide
BG106605A BG66093B1 (en) 1999-09-28 2002-04-11 Controlled release compositions comprising nimesulide
US11/545,718 US20070128276A1 (en) 1999-09-28 2006-10-10 Controlled release compositions comprising nimesulide
US11/978,162 US20080160082A1 (en) 1999-09-28 2007-10-26 Controlled release compositions comprising Nimesulide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1297DE1999 1999-09-28
IN1297/DEL/99 1999-09-28

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/545,718 Continuation-In-Part US20070128276A1 (en) 1999-09-28 2006-10-10 Controlled release compositions comprising nimesulide
US11/978,162 Continuation US20080160082A1 (en) 1999-09-28 2007-10-26 Controlled release compositions comprising Nimesulide

Publications (3)

Publication Number Publication Date
WO2001022791A2 WO2001022791A2 (en) 2001-04-05
WO2001022791A3 true WO2001022791A3 (en) 2002-01-31
WO2001022791A8 WO2001022791A8 (en) 2002-10-31

Family

ID=11092667

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2000/000094 WO2001022791A2 (en) 1999-09-28 2000-09-27 Controlled release compositions comprising nimesulide

Country Status (26)

Country Link
US (2) US20070128276A1 (en)
EP (1) EP1218889B1 (en)
JP (2) JP4359412B2 (en)
KR (1) KR100621281B1 (en)
CN (2) CN1399543A (en)
AP (1) AP1954A (en)
AT (1) ATE450865T1 (en)
AU (1) AU774099B2 (en)
BG (1) BG66093B1 (en)
BR (1) BR0014383A (en)
CA (1) CA2385890C (en)
CZ (1) CZ20021076A3 (en)
DE (1) DE60043447D1 (en)
DK (1) DK1218889T3 (en)
ES (1) ES2337547T3 (en)
HU (1) HUP0204451A3 (en)
IL (2) IL148864A0 (en)
MX (1) MXPA02003321A (en)
NO (1) NO20021540L (en)
NZ (1) NZ518052A (en)
PT (1) PT1218889E (en)
RS (1) RS50303B (en)
RU (1) RU2238087C2 (en)
UA (1) UA80667C2 (en)
WO (1) WO2001022791A2 (en)
ZA (1) ZA200202411B (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1684725A1 (en) * 2003-10-31 2006-08-02 Elan Pharma International Limited Novel nimesulide compositions
US20070196396A1 (en) * 2004-02-11 2007-08-23 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
WO2006084164A2 (en) * 2005-02-01 2006-08-10 Emisphere Technologies, Inc. Gastric retention and controlled release delivery system
CA2614850A1 (en) * 2005-07-20 2007-01-25 Panacea Biotec Ltd. Novel pharmaceutical modified release dosage form cyclooxygenase enzyme inhibitor
CN100346778C (en) * 2005-07-22 2007-11-07 海南康力元药业有限公司 Nimesulide sustained release medicinal composition
US20090258947A1 (en) * 2006-04-24 2009-10-15 Rajesh Jain Novel low dose pharmaceutical compositions comprising nimesulide, preparation and use thereof
EP2155170A2 (en) 2007-06-08 2010-02-24 Addrenex Pharmaceuticals, Inc. Extended release formulation and method of treating adrenergic dysregulation
BE1018280A3 (en) * 2008-09-09 2010-08-03 Squarepoint Pointcarre Sprl EXTENDED RELEASE NIMESULIDE COMPOSITION.
EP2346351B1 (en) * 2008-09-22 2019-07-03 Rubicon Research Private Limited Compositions exhibiting delayed transit through the gastrointestinal tract
EP2403487A2 (en) * 2009-03-04 2012-01-11 Fdc Limited Oral controlled release dosage forms for water soluble drugs
US20120064159A1 (en) * 2009-05-28 2012-03-15 Aptapharma, Inc. Multilayer Oral Tablets Containing a Non-Steroidal Anti-Inflammatory Drug and/or Acetaminophen
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
CN102188386B (en) * 2010-03-02 2013-09-04 海南葫芦娃制药有限公司 Nimesulide sustained-release pellets and preparation method thereof
CN102232928A (en) * 2010-04-20 2011-11-09 广州艾格生物科技有限公司 Nimesulide sustained-release suspension and preparation method thereof
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
CN102485220A (en) * 2010-12-03 2012-06-06 沈阳药科大学 Nimesulide monolayer osmotic pump controlled release tablet
WO2012159077A2 (en) * 2011-05-18 2012-11-22 Board Of Regents, The University Of Texas System Multiple dosing regimen oral drug delivery platform
CN103142565B (en) * 2012-04-18 2015-04-29 中国人民解放军军事医学科学院毒物药物研究所 Novel nimesulide sustained-release pharmaceutical composition and preparation method thereof
EP3105226B1 (en) 2014-02-13 2019-09-04 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
CR20200199A (en) 2014-02-13 2020-06-19 Incyte Corp Cyclopropylamines as lsd1 inhibitors
US20150275167A1 (en) * 2014-03-28 2015-10-01 Corning Incorporated Composition and method for cell culture sustained release
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
CN105435239B (en) * 2014-08-29 2019-04-26 武汉光谷人福生物医药有限公司 Mei Suoshuli Film coated tablets and preparation method thereof
AU2016243939B2 (en) 2015-04-03 2020-09-03 Incyte Holdings Corporation Heterocyclic compounds as LSD1 inhibitors
WO2016189481A1 (en) * 2015-05-25 2016-12-01 Sun Pharmaceutical Industries Limited Once daily oral pharmaceutical composition of isotretinoin
TWI765860B (en) 2015-08-12 2022-06-01 美商英塞特公司 Salts of an lsd1 inhibitor
US9687475B1 (en) 2016-03-24 2017-06-27 Ezra Pharma Llc Extended release pharmaceutical formulations with controlled impurity levels
US9675585B1 (en) 2016-03-24 2017-06-13 Ezra Pharma Extended release pharmaceutical formulations
WO2018190621A1 (en) * 2017-04-10 2018-10-18 성균관대학교 산학협력단 Extended release preparation comprising porous gastroretentive layer, and preparation method therefor
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2129010A1 (en) * 1997-01-02 1999-05-16 Gold Oscar Proceeding for the preparation of the prolonged action granule compound containing 4-nitro-2-phenoxymethanesulfonanilide
EP1005865A1 (en) * 1998-11-10 2000-06-07 Panacea Biotec Limited A anti-allergy anti-inflammatory composition comprising nimesulide and cetirizine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4424235A (en) * 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
US4666928A (en) * 1984-08-30 1987-05-19 Merck Frosst Canada, Ind. Propylphenoxy pyridine carboxylates as leukotriene antagonists
IT1215726B (en) * 1988-01-18 1990-02-22 Alfa Wassermann Spa GALENIC FORMULATIONS WITH SCHEDULED SALE.
IN187379B (en) * 1996-04-12 2002-04-13 Panacea Biotec Ltd
EP0906106B1 (en) * 1996-05-23 2008-05-07 Novartis AG Prevention and treatment of colonic adenoma or colonic microadenoma by 6-fluoroursodeoxycholic acid (6-fudca)
IN186315B (en) * 1996-12-12 2001-08-04 Panacea Biotec Ltd
US5948787A (en) * 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
EP1017370B1 (en) * 1997-09-11 2003-10-29 Nycomed Danmark ApS MODIFIED RELEASE MULTIPLE-UNITS COMPOSITIONS OF NON-STEROID ANTI-INFLAMMATORY DRUG SUBSTANCES (NSAIDs)
IN188720B (en) * 1997-11-06 2002-11-02 Panacea Biotec Ltd
FR2772615B1 (en) * 1997-12-23 2002-06-14 Lipha MULTILAYER TABLET FOR INSTANT RELEASE THEN PROLONGED ACTIVE SUBSTANCES
US6184220B1 (en) * 1998-03-27 2001-02-06 Boehringer Ingelheim Pharma Kg Oral suspension of pharmaceutical substance

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2129010A1 (en) * 1997-01-02 1999-05-16 Gold Oscar Proceeding for the preparation of the prolonged action granule compound containing 4-nitro-2-phenoxymethanesulfonanilide
EP1005865A1 (en) * 1998-11-10 2000-06-07 Panacea Biotec Limited A anti-allergy anti-inflammatory composition comprising nimesulide and cetirizine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GUO ET AL: "Preparation and in vitro dissolution of nimesulide sustained - release tablets", CHEMABS, XP002148832 *
MANNA ET AL: "Design and evaluation of an oral controlled release microparticulate drug delivery system of nimesulide by ionotropic gelation technique and statistical optimization by factorial analysis", JOURNAL OF SCIENTIFIC AND INDUSTRIAL RESEARCH, XP001064400 *
NAGOJI K.E.V. ET AL: "Release studies of nimesulide from ethyl cellulose and ethyl cellulose and hydroxy propyl methyl cellulose matrices.", INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, (2000) 62/6 (482-484)., XP001063992 *

Also Published As

Publication number Publication date
ES2337547T3 (en) 2010-04-27
AU2879901A (en) 2001-04-30
NO20021540L (en) 2002-05-28
ATE450865T1 (en) 2009-12-15
AP1954A (en) 2009-02-10
CN1399543A (en) 2003-02-26
KR100621281B1 (en) 2006-09-13
US20080160082A1 (en) 2008-07-03
CA2385890A1 (en) 2001-04-05
DK1218889T3 (en) 2010-04-12
BG66093B1 (en) 2011-04-29
KR20020097138A (en) 2002-12-31
JP2003534236A (en) 2003-11-18
IL148864A (en) 2008-06-05
RU2002111365A (en) 2004-01-27
UA80667C2 (en) 2007-10-25
WO2001022791A2 (en) 2001-04-05
IL148864A0 (en) 2002-09-12
MXPA02003321A (en) 2004-09-10
CA2385890C (en) 2007-04-03
RS50303B (en) 2009-09-08
JP2007217436A (en) 2007-08-30
CN101804041A (en) 2010-08-18
JP4359412B2 (en) 2009-11-04
BR0014383A (en) 2002-10-22
HUP0204451A2 (en) 2003-06-28
CZ20021076A3 (en) 2002-08-14
HUP0204451A3 (en) 2004-05-28
DE60043447D1 (en) 2010-01-14
PL358369A1 (en) 2004-08-09
US20070128276A1 (en) 2007-06-07
ZA200202411B (en) 2003-06-26
BG106605A (en) 2002-12-29
YU23402A (en) 2004-12-31
NO20021540D0 (en) 2002-03-27
NZ518052A (en) 2005-04-29
WO2001022791A8 (en) 2002-10-31
PT1218889E (en) 2010-03-08
EP1218889A2 (en) 2002-07-03
EP1218889B1 (en) 2009-12-02
RU2238087C2 (en) 2004-10-20
AU774099B2 (en) 2004-06-17

Similar Documents

Publication Publication Date Title
WO2001022791A8 (en) Controlled release compositions comprising nimesulide
HUP0302319A3 (en) Pharmaceutical composition for oral administration of active ingredient
WO2004066910A8 (en) Controlled release modifying complex and pharmaceutical compositions thereof
AU2002357012A1 (en) Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
WO2000019985A3 (en) New sustained release oral formulations
MXPA02003596A (en) Novel pharmaceutical compositions of anti-tubercular drugs and process for their preparation.
AU2001263229A1 (en) Compositions and methods for administration of pharmacologically active compounds
IL219820A0 (en) Hydrophilic controlled release formulation comprising pregelatinized starch for controlled release of an active component
AU2001254711A1 (en) Sustained release vitamin composition
AU2002239282A1 (en) Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
AU2003274681A1 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
WO2007009806A3 (en) Solid dosage formulations of narcotic drugs having improved buccal adsorption
HUP0203312A3 (en) Pharmaceutically active sulfonamide derivatives, process for their preparation, and pharmaceutical compositions and their use
CA2294783A1 (en) Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
WO2004108162A3 (en) Controlled release pharmaceutical composition
AU2003270255A1 (en) Fast releasing, solid administration form for oral application of active ingredients which are hard to dissolve
HK1067626A1 (en) Novel 2h-pyridazine-3-one derivatives, pharmaceutical compositions containing the same and a process for the preparation of the active ingredient
WO2002024203A3 (en) Controlled release formulations for oral administration
WO2002026191A3 (en) Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
WO2002011694A3 (en) Compositions and dosage forms for application in the oral cavity in the treatment of mykoses
WO2005065639A3 (en) Novel pharmaceutical compositions
AU2001227030A1 (en) Pharmaceutical composition for controlled release of an active ingredient
WO2005051350A3 (en) Water dispersible tablet
TR200200683T2 (en) Oral controlled release formulations.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-234/02

Country of ref document: YU

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 148864

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2002/02411

Country of ref document: ZA

Ref document number: 28799/01

Country of ref document: AU

Ref document number: 518052

Country of ref document: NZ

Ref document number: 200202411

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2001 526021

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV2002-1076

Country of ref document: CZ

Ref document number: PA/a/2002/003321

Country of ref document: MX

Ref document number: 2385890

Country of ref document: CA

Ref document number: 1020027003996

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2000IN 200000094

Country of ref document: KE

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2000IN200000094

Country of ref document: KE

Ref document number: 2002/00848

Country of ref document: TR

ENP Entry into the national phase

Ref document number: 2000 106605

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 008144249

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2000992052

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000992052

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2002-1076

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WR Later publication of a revised version of an international search report
WWP Wipo information: published in national office

Ref document number: 1020027003996

Country of ref document: KR

WSNC Later publication of a supplementary international search report together with a suppl. search report established by non-competent authority
WWG Wipo information: grant in national office

Ref document number: 28799/01

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 518052

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 518052

Country of ref document: NZ

WWR Wipo information: refused in national office

Ref document number: 1020027003996

Country of ref document: KR